• Product NameAICAR (Acadesine)
• Brief DescriptionInhibitors
• Purification99.71%
• Biological ActivityAcadesine (AICA-riboside) is a purine nucleoside analog with anti-ischemic properties that is currently being studied (Phase 3) for the prevention of adverse cardiovascular outcomes in patients undergoing coronary artery bypass graft (CABG) surgery. It is being developed jointly by PeriCor and Schering-Plough. Acadesine has been granted Orphan Drug Designation for B-CLL in the EU.
• Target NameAMPK activator
• CAS No. 2627-69-2
• Calculated MW 258.24
• Formulation C9H14N4O5
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Metabolism system
  SMILES:C1=NC(=C(N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)N)C(=O)N
  Pathways:PI3K/Akt/mTOR signaling
  Receptor:AMPK
  Boling pt:726.3C
  Melting pt:214-215C
  Solubility:DMSO: 51 mg/mL (197.49 mM)
  Appearance:White Crystal
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Corton JM, et al. Eur J Biochem, 1995, 229(2), 558-565.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting